Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1-negative or weakly positive advanced non-small-cell lung cancer after disease progression on platinum-based therapy. (EMERALD study) (WJOG10317L)
Phase of Trial: Phase III
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary) ; Atezolizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms EMERALD study; RAM+DOC vs Atezo
- 06 Mar 2019 Status changed from not yet recruiting to recruiting.
- 27 Mar 2018 Planned initiation date changed from 1 May 2018 to 27 Mar 2018.
- 07 Mar 2018 New trial record